Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Chugai to Transfer Japan Rights for 3 Topical Maxacalcitol Products to Maruho
Chugai Pharmaceutical will transfer its Japan rights for three dermatological products containing maxacalcitol to Maruho on December 1, 2019, the two companies said on January 30. The three agents are Oxarol Ointment and Lotion for the treatment of keratosis including…
To read the full story
Related Article
- Chugai to Divest Oxarol Injection to LTL in Japan
August 29, 2024
- Chugai Completes Transfer of 3 Dermatology Products to Maruho
December 3, 2019
BUSINESS
- Sandoz to Sell, Distribute G-Lasta Biosimilar in Japan
August 26, 2026
- Astellas Starts Global PIII of ASP2138 in Gastric Cancer
August 26, 2026
- Chugai Files Vamikibart in Japan for Uveitic Macular Edema
August 26, 2026
- FDA Extends Review of Capricor’s DMD Cell Therapy by 3 Months
August 26, 2026
- Leqembi Iqlik Now Available for Alzheimer’s Initiation Use in US
August 25, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…